Search the Newsreel

Illumina Earnings: Strong Instrument Sales and Growing AI Opportunities Boost 2026 Outlook

Illumina Looks Likely To Benefit From AI Initiatives in Life Sciences

Illumina is expected to gain from the growing integration of AI in life sciences, as highlighted by strong instrument sales and increasing AI opportunities boosting its 2026 outlook. The company's strategy involves leading genomic sequencing through innovation and acquisitions, addressing broad applications from population …

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations

Illumina (NASDAQ:ILMN) reported strong Q2 CY2026 results, with revenue of $1.16 billion exceeding analyst expectations and sales up 9.4% year-on-year. The company also raised its full-year revenue guidance to $4.62 billion and adjusted EPS guidance to $5.35 at the midpoint, both slightly above analyst …

Illumina’s 43% quarter meets a 58% Fair Value premium and thin volume near the high

Illumina closed at $194.10, only 2.5% below its 52-week high, but the latest 4.0% advance came on 0.8x 13-week average volume.

Earnings Flash (ILMN) Illumina, Inc. Posts Q2 Adjusted EPS $1.31 per Share, vs. FactSet Est of $1.23

Illumina, Inc. (ILMN) announced its Q2 adjusted EPS of $1.31 per share, surpassing FactSet’s estimate of $1.23. The company also reported Q2 revenue of $1.16 billion, exceeding FactSet's estimate of $1.13 billion, and provided earnings guidance for fiscal year 2026. The news highlighted the …

Earnings Flash (ILMN) Illumina, Inc. Reports Q2 Revenue $1.16B, vs. FactSet Est of $1.13B

Illumina, Inc. (ILMN) reported its second-quarter revenue at $1.16 billion, surpassing FactSet's estimate of $1.13 billion. The company specializes in DNA sequencing and array-based technologies for research, clinical, and applied markets, with products used in life sciences, oncology, reproductive health, and agriculture. Illumina also …

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 results Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 …

Illumina, Inc. (Nasdaq: ILMN) lifts 2026 outlook after Q2 revenue hits $1.16B

Illumina, Inc. (Nasdaq: ILMN) reported strong Q2 2026 financial results with revenue reaching $1.16 billion, a 9.5% increase from the previous year. This performance led the company to raise its full-year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP diluted EPS guidance to $5.30-$5.40. …

Illumina Inc. stock outperforms competitors on strong trading day

Illumina Inc. (ILMN) saw its stock rise by 5.27% to $205.09 on Thursday, contributing to its third consecutive day of gains. This performance outpaced the broader market, which also experienced a strong trading day with the S&P 500 Index rising 1.66% and the Dow …

Illumina (ILMN) Reports Q2 Earnings: What Key Metrics Have to Say

Illumina Fiscal Q2 Earnings, Revenue Rise; 2026 Guidance Revised

Illumina (ILMN) Tops Q2 Earnings and Revenue Estimates

ILLUMINA, INC. (ILMN) names Chief Commercial Officer as insider with no holdings

Illumina, Inc. (ILMN) identified Michael C. Sullivan, its Chief Commercial Officer, as a reporting person for insider ownership purposes. This Form 3 filing indicates that Sullivan currently holds no reportable equity, derivative positions, or insider transactions with the company. The disclosure establishes his insider …

Illumina Earnings: What To Look For From ILMN

Illumina Earnings: What To Look For From ILMN Genomics company Illumina (NASDAQ:ILMN) will be announcing earnings results this Thursday after market close. Here's what to expect. Illumina beat analysts' revenue expectations last quarter, reporting revenues of $1.09 billion, up 4.8% year on year. It …

Insights Into Illumina (ILMN) Q2: Wall Street Projections for Key Metrics

In its upcoming report, Illumina (ILMN) is predicted by Wall Street analysts to post quarterly earnings of $1.23 per share, reflecting an increase of 3.4% compared to the same period last year. Revenues are forecasted to be $1.12 billion, representing a year-over-year increase of …

Illumina Inc (ILMN) Valuation: PE, PB & Fair Value Analysis

Illumina Inc (ILMN) currently holds a valuation score of 9.61, positioning it 8th out of 199 companies in the Healthcare Equipment & Supplies industry. Its current P/E ratio is 34.86, which is slightly below its recent high but significantly above its recent low. The …

Illumina Inc (ILMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Illumina Inc (ILMN), detailing its current price momentum score of 3.44 and suggesting it's suitable for range-bound swing trading between resistance at $203.15 and support at $178.79. It evaluates various technical indicators like MACD, RSI, and moving …

Illumina, Inc. Revenue Breakdown – LSX:927079

This article provides a revenue breakdown for Illumina, Inc. (LSX:927079), detailing its performance in the last fiscal year. The company generated 3.70 billion EUR, with its Core Illumina - Consumables segment being the top contributor at 2.75 billion EUR. Geographically, the United States was …

Illumina CIO: In the AI Era, ‘Tech Leaders Are in the Driver’s Seat’

Illumina CIO Mark Field asserts that technology leaders are currently making critical decisions as AI transforms industries, positioning them in the "driver's seat." He emphasizes the importance of reimagining IT organizations around AI, fostering AI fluency within teams, and transitioning IT from an order-taker …

Illumina Inc (ILMN) finishes latest week with a 42.9% 12-week climb

The diagnostics and research stock remains in an active weekly trend, but lighter volume and modest Relative Strength keep the setup mixed.

Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences

Standard BioTools (NASDAQ: LAB) has announced key updates to advance its merger with Treeline Biosciences. The company is selling its Mass Cytometry business to Multiplex Bio for up to $10 million, ensuring continuity of its CyTOF and Hyperion product lines. Additionally, Standard BioTools received …

Standard BioTools Sells Mass Cytometry Business and Secures $30 Million Illumina Buyout Ahead of Treeline Merger

Standard BioTools Inc. has announced strategic transactions aimed at streamlining its business and bolstering its balance sheet before its planned merger with Treeline Biosciences. The company sold its Mass Cytometry business to Multiplex Bio for up to $10 million, secured a $30 million buyout …

Illumina Inc. stock underperforms Monday when compared to competitors

Illumina Inc. stock dropped 2.38% on Monday, closing at $189.47, despite a generally positive day for the broader stock market. The S&P 500 Index saw a slight increase of 0.02%, and the Dow Jones Industrial Average rose by 0.51%. This marked the second consecutive …

(ILMN) as a Liquidity Pulse for Institutional Tactics

This article provides an in-depth analysis of Illumina Inc. (NASDAQ: ILMN), focusing on institutional trading tactics and AI-generated signals. It highlights strong near-term sentiment, potential resistance testing, and an exceptional short-sell opportunity with a significant risk-reward ratio. The report also outlines three distinct trading …

Illumina Inc (ILMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for Illumina Inc (ILMN) by business segments and geographic regions. As of April 6, 2026, Consumables represent the largest segment at 74.30% of revenue, while the United States accounts for over half of the company's regional revenue. …

Illumina stock trades steady as investors weigh restructuring and recovery prospects

Illumina's stock performance reflects ongoing restructuring efforts and the demand for core sequencing products. Investors are closely watching the company's recent divestments, margin improvements, and balance sheet strength to assess its potential for recovery in the genomics equipment market. Key drivers for future growth …

EXEL vs. ILMN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Illumina (ILMN). But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out. There are …

ILMN6231083 Bond Profile — Key Metrics

This article provides key metrics for the Illumina, Inc. (ILMN) bond, ISIN ILMN6231083. It details the bond's issue date, maturity date, outstanding amount, face value, and coupon rate, alongside a brief description of Illumina, Inc. The bond has a 4.75% coupon and matures on …

Eli Lilly (LLY) Joins Illumina Atlas To Map Disease With AI

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Eli Lilly (NYSE:LLY) has joined the Illumina Billion Cell Atlas as a founding member, …

Illumina Inc (ILMN) weekly rebound broadens as 12-week gain hits 41.4%

The sequencing and diagnostics name is showing trend support, though relative strength remains a constraint on the setup.

Illumina’s 56% quarter nears a 52-week high despite narrow diagnostics trend breadth

Illumina closed just 0.4% below its 52-week high after another strong week, but average volume and selective industry participation keep the confirmation bar in view.

Illumina sets July 30 call on second-quarter 2026 results

Illumina (ILMN) Jumps On Earnings And Guidance As Valuation Questions Remain

Illumina keeps a 9-week Trend Signal while diagnostics peers remain uneven

The sequencing specialist slipped 0.8% for the week, but a 29.5% 12-week advance, positive Market Dynamics and an active Trend Signal keep the weekly profile constructive. Confirmation is not complete, with volume only 1.1x the 13-week norm

5 Revealing Analyst Questions From Illumina’s Q1 Earnings Call

Assessing Illumina (ILMN) Valuation After Earnings Beat Guidance Hike And Expanded Buyback